University of Washington, 850 Republican St, Seattle, WA 98109; e-mail:
Am J Clin Pathol. 2013 Dec;140(6):838-44. doi: 10.1309/AJCPE4PK6CTBNQJY.
To determine the clinical utility of p63 expression, which has been identified in several cohorts as a predictor of poorer prognosis in Merkel cell carcinoma (MCC).
Immunohistochemistry was used to determine p63 expression on MCC tumors from 128 patients.
Of the patients, 33% had detectable p63 expression. p63 Positivity was associated with an increased risk of death from MCC (hazard ratio, 2.05; P = .02) in a multivariate Cox regression model considering stage at presentation, age at diagnosis, and sex. Although p63 expression correlated with diminished survival in this largest cohort reported thus far, the effect was weaker than that observed in prior studies. Indeed, within a given stage, p63 status did not predict survival in a clinically or statistically significant manner.
It remains unclear whether this test should be integrated into routine MCC patient management.
确定 p63 表达的临床效用，在多个队列中，p63 被鉴定为 Merkel 细胞癌 (MCC) 预后不良的预测因子。
使用免疫组织化学方法检测 128 例 MCC 肿瘤中的 p63 表达。
在这些患者中，有 33% 的患者可检测到 p63 表达。多变量 Cox 回归模型考虑到就诊时的分期、诊断时的年龄和性别，p63 阳性与 MCC 死亡风险增加相关（风险比，2.05；P =.02）。尽管 p63 表达与迄今为止报道的最大队列中生存时间缩短相关，但该效应弱于先前的研究。实际上，在给定的分期内，p63 状态并未以临床或统计学上显著的方式预测生存。
目前尚不清楚是否应将该检测纳入 MCC 患者的常规管理中。
